The latest biotech news - Labiotech.eu

Home News and Trends Page 317

Latest Posts

xCelligence ols biosciences car t cancer cytotoxicity assay

News and Trends 12 Apr 2016

How CAR-T Cells Kill Cancer: Pictures start Moving

CAR-T is a groundbreaking personalized cancer therapy with tremendous potential to drive the patient’s own immune cells to specifically target and kill cancer cells. Because the development of this therapy is still in the early phase, new tools are needed to provide a quick potency assay to assess the cytotoxicity of the therapeutic T-cells prior […]

April 12, 2016 - 6 minutesmins - By Jerome Topsent

europe biotech ey finance growth pharma industry 2016

News and Trends 12 Apr 2016

How was the Biotech Financial World in 2015? Unprecedented!

Biotech is still breaking funding records. A new report by EY provides an interesting analysis of how Biotech is doing, globally and in Europe. Although 2015 was the best for Biotech yet, but there is a slowdown coming – that’s the gist of EY’s recent report: ‘Beyond borders 2016: Biotech financing‘. This well-known auditing and […]

April 12, 2016 - 3 minutesmins - By Denise Neves Gameiro

Genentech birthday 40 biotechnology cohen boyer swanson

News and Trends 11 Apr 2016

Modern Biotechnology is Now 40 – Happy Birthday!

Genentech has turned 40 years old this month – quite a milestone for the pioneer of modern biotechnology, which is still rocking it in San Francisco, US. It all began with an experiment conducted by a team led by Herbert Boyer of the University of California San Francisco (UCSF), studying antibiotic resistance plasmids in E. […]

April 11, 2016 - 3 minutesmins - By Denise Neves Gameiro

world parkinson parkinsons disease awareness day CNS biotech neurological neurodegenerative

News and Trends 11 Apr 2016

It’s World Parkinson’s Disease Day! #EndParkinsons

Today (April 11th) is the birthday of the memorable Dr James Parkinson, who discovered this major neurodegenerative disease. So what is Parkinson’s Disease, and who is researching it? First described in 1817 by James Parkinson, Parkinson’s Disease (PD) is the second most common chronic progressive neurodegenerative disorder in the elderly after Alzheimer’s. Since PD mainly affects […]

April 11, 2016 - 4 minutesmins - By Dani Bancroft

medday multiple sclerosis neurodegenerative disease md1003

News and Trends 11 Apr 2016

French Biotech gets €34M to bring Multiple Sclerosis Drug to the US

MedDay (France) has raised €34M that should help pay a US phase III for its leading candidate for Multiple Sclerosis – as well as its commercial launch in Europe. Based in Paris, MedDay is a Biotech developing new drugs targeting brain metabolism to treat diseases of the nervous system. Its leading candidate, MD1003, has a mixed track record. […]

April 11, 2016 - 3 minutesmins - By Denise Neves Gameiro

lipigon astrazeneca lipoprotein lipase lpl cardiovascular

News and Trends 11 Apr 2016

Swedish Startup close to the North Pole signs 100 million deal with AstraZeneca

Lipigon Pharmaceuticals will now count with AstraZeneca to push the development of its Lipoprotein Lipase strategies. This could produce novel drugs to tackle metabolic and cardiovascular disease, still the leading cause of death worldwide. Lipigon is a spinout of Umeå University, developing new drugs based on research of lipid metabolism. Umeå may have one of the most remote universities […]

April 11, 2016 - 3 minutesmins - By Denise Neves Gameiro

ADVERTISEMENT

center genomic gastronomy denfeld kramer

News and Trends 9 Apr 2016

BioArt & Genomic Gastronomy: Glowing Sushi, ‘Smog Tasting’ and Gamma Gardens

The Center for Genomic Gastronomy in Dublin (Ireland) curates an unusual type of BioArt which makes us think about how we see food and technology – through fluorescent sushi, ‘Smog candy’ and radiation-bred sauces. Describing themselves as an ‘artist-led think tank‘, the Center for Genomic Gastronomy (CGG for short) is making witty projects that range from cook-offs and […]

April 9, 2016 - 5 minutesmins - By Denise Neves Gameiro

biotech week activartis header

News and Trends 8 Apr 2016

Biotech of the Week: Activartis Immuno-Oncology in Vienna

This week, we leave Milan and head once again towards the East. Vienna: Austria’s palatial and stunning capital city is our destination, and is also where our Biotech of the week, Activartis, is located. City: Vienna (Austria) Founded: 2003 Employees: 11 – 50 (as of 12/2015) Financial Data: N/A CEO: Thomas Felzmann Mission: Currently in phase II clinical […]

April 8, 2016 - 1 minutemin - By Joachim Eeckhout

spix meiogenix bayer crop gene technology crispr food meiotic spo11 recombination biotech agriculture

News and Trends 8 Apr 2016

French Gene Technology and Bayer to ‘Unlock’ Food Crop Diversity

Meiogenix (France) has signed with Bayer Crop Science (Germany) for use of their gene-editing platform, to try and ‘Unlock’ crop genetic diversity and improve food security. Launched in 2011, this Parisian biotech was a spin-off of the Institut Curie and the French Agricultural Agency (INRA) after successfully raised funding. Now, under this non-exclusive agreement, Meiogenix […]

April 8, 2016 - 3 minutesmins - By Dani Bancroft

heptares allergan neurological alzheimer gpcr

News and Trends 7 Apr 2016

Allergan Signs Massive €3Bn Alzheimer’s Deal with UK Biotech

Heptares Therapeutics is licensing its portfolio of novel candidates for neurological diseases, including one for Alzheimer’s, to Allergan for up to €3Bn. A good way for Allergan to ‘get over’ yesterday’s failed Pfizer acquisition. Based in Cambridge, UK, Heptares Therapeutics is creating new therapies with their StaR platform, that allows it to target G protein-coupled receptors (GPCRs), a superfamily of 375 receptors linked to many […]

April 7, 2016 - 3 minutesmins - By Denise Neves Gameiro

morphosys galapagos inflammatory mor106 mab

News and Trends 7 Apr 2016

Two of the Biggest European Biotechs launch Antibody Program together

MorphoSys (Germany) and Galapagos (Belgium) have announced a new joint program to conduct a phase I trial for a first-in-class antibody, MOR106, that could be used to treat inflammatory diseases. Just after announcing that it is suing Janssen Biotech and Genmab (Denmark), Munich-based MorphoSys is still keeping things interesting – this time with a phase I trial for […]

April 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

tunicates pharma mar sea squirt alplidin trial cancer multiple myeloma

News and Trends 7 Apr 2016

This Successful Phase III Cancer Drug comes from Sea Squirts

PharmaMar is closer to have another cancer drug on the market, after the success of phase III trials with Aplidin for Multiple Myeloma. Based in Madrid, PharmaMar is a Biopharma developing anti-cancer drugs, with an interesting strategy for drug discovery. It researches compounds present in marine organisms and assess if they have any biological action […]

April 7, 2016 - 2 minutesmins - By Denise Neves Gameiro

ADVERTISEMENT